Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: Raising expectations for exploratory clinical trials

Expert Opinion on Drug Discovery

Volumn 8, Issue 8, 2013, Pages 965-976

  Higashijima, Yoshiki ^a   Tanaka, Tetsuhiro ^a   Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anemia; Erythropoiesis stimulating agent; Exploratory clinical trials; Hypoxia inducible factor; Prolyl hydroxylase domain containing protein inhibitor; Structure based drug design

Indexed keywords

8 QUINOLINOL DERIVATIVE; ALOGLIPTIN; HYPOXIA INDUCIBLE FACTOR; IMIDAZOPYRIDINE DERIVATIVE; JNJ 42041935; NILOTINIB; OXYGENASE INHIBITOR; RALTITREXED; TM 6008; TM 6089; UNCLASSIFIED DRUG;

ANEMIA; CLINICAL TRIAL (TOPIC); DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; ERYTHROPOIESIS; ERYTHROPOIESIS STIMULATING AGENT RESISTANT ANEMIA; EXPLORATORY RESEARCH; HUMAN; IRON CHELATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANEMIA; ANIMALS; DRUG DESIGN; DRUG RESISTANCE; HEMATINICS; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; PROLYL-HYDROXYLASE INHIBITORS;

EID: 84880750873     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.796358     Document Type: Review

References (101)

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352(10):1011-23
2. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162(12):1401-8
3. Nangaku M, Fliser D. Erythropoiesis-stimulating agents: past and future. Kidney Int Suppl 2007(107):S1-3
4. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23(10):1631-4
5. Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993;44(5):1149-62
6. Obara N, Suzuki N, Kim K, et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 2008;111(10):5223-32
7. Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011;121(10):3981-90
8. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252(15):5558-64
9. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313(6005):806-10
10. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82(22):7580-4
11. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321(3):158-63
12. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111(12):992-1000
13. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2(8517):1175-8
14. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-98
15. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355(20):2071-84
16. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-32
17. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74(6):791-8
18. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146-55
19. Fraisl P, Aragones J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 2009;8(2):139-52
20. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21(12):2151-6
21. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292(5516):468-72
22. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292(5516):464-8
23. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002;16(10):1151-62
24. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295(5556):858-61
25. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 ( EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11(1):72-82
26. Ema M, Taya S, Yokotani N, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94(9):4273-8
27. Hu CJ, Sataur A, Wang L, et al. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 2007;18(11):4528-42
28. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002;13(7):1721-32
29. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005;105(8):3133-40
30. Warnecke C, Zaborowska Z, Kurreck J, et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 2004;18(12):1462-4
31. Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008;358(2):162-8
32. Ehrismann D, Flashman E, Genn DN, et al. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J 2007;401(1):227-34
33. Koivunen P, Hirsila M, Kivirikko KI, Myllyharju J. The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J Biol Chem 2006;281(39):28712-20
34. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 2002;296(2):343-9
35. Koivunen P, Tiainen P, Hyvarinen J, et al. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem 2007;282(42):30544-52
36. Laitala A, Aro E, Walkinshaw G, et al. Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood 2012;120(16):3336-44
37. Metzen E, Berchner-Pfannschmidt U, Stengel P, et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 2003;116(Pt 7):1319-26
38. Willam C, Maxwell PH, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 2006;41(1):68-77
39. Lieb ME, Menzies K, Moschella MC, et al. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 2002;80(4):421-6
40. Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279(37):38458-65
41. Marxsen JH, Stengel P, Doege K, et al. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J 2004;381(Pt 3):761-7
42. Berra E, Benizri E, Ginouves A, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003;22(16):4082-90
43. Takeda K, Ho VC, Takeda H, et al. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 2006;26(22):8336-46
44. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008;40(2):170-80
45. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008;111(6):3229-35
46. Minamishima YA, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008;111(6):3236-44
47. Evstatiev R, Gasche C. Iron sensing and signalling. Gut 2012;61(6):933-52
48. Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs 2011;20(5):645-56
49. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997;272(32):20055-62
50. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 1999;274(34):24147-52
51. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274(34):24142-6
52. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275(28):21048-54
53. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010;116(16):3039-48
54. Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009;119(5):1159-66
55. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117(7):1926-32
56. Takubo K, Goda N, Yamada W, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010;7(3):391-402
57. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011;17(15):4936-41
58. Forristal CE, Winkler IG, Nowlan B, et al. Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood 2013;121(5):759-69
59. Andricopulo AD, Salum LB, Abraham DJ. Structure-based drug design strategies in medicinal chemistry. Curr Top Med Chem 2009;9(9):771-90
60. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-83
61. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 2012;17(19-20):1088-102
62. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6(3):211-19
63. Kalyaanamoorthy S, Chen YP. Structure-based drug design to augment hit discovery. Drug Discov Today 2011;16(17-18):831-9
64. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409(6822):860-921
65. Shoichet BK. Virtual screening of chemical libraries. Nature 2004;432(7019):862-5
66. Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997;2(10):436-44
67. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 2000;89(2):145-54
68. Hou T, Xu X. Recent development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 2004;10(9):1011-33
69. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44(1):235-49
70. Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Brief Bioinform 2009;10(5):579-91
71. Fujiwara S, Yamashita F, Hashida M. Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network. Int J Pharm 2002;237(1-2):95-105
72. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999;88(8):815-21
73. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998;27:249-84
74. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-41
75. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51(20):5579-86
76. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50(10):2297-300
77. McDonough MA, McNeill LA, Tilliet M, et al. Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc 2005;127(21):7680-1
78. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82(12):3610-15
79. Salnikow K, Donald SP, Bruick RK, et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004;279(39):40337-44
80. Sridharan V, Guichard J, Bailey RM, et al. The prolyl hydroxylase oxygen-sensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition. Am J Physiol Cell Physiol 2007;292(2):C719-28
81. Freret T, Valable S, Chazalviel L, et al. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci 2006;23(7):1757-65
82. Tanaka T, Matsumoto M, Inagi R, et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int 2005;68(6):2714-25
83. Tanaka T, Kojima I, Ohse T, et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 2005;85(10):1292-307
84. Chiang CK, Tanaka T, Inagi R, et al. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest 2011;91(11):1564-71
85. McDonough MA, Li V, Flashman E, et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA 2006;103(26):9814-19
86. Warshakoon NC, Wu S, Boyer A, et al. Design and synthesis of a series of novel pyrazolopyridines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 2006;16(21):5687-90
87. Warshakoon NC, Wu S, Boyer A, et al. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 2006;16(21):5517-22
88. Nangaku M, Izuhara Y, Takizawa S, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 2007;27(12):2548-54
89. Barrett TD, Palomino HL, Brondstetter TI, et al. Pharmacological characterization of 1-(5-chloro-6- (trifluoromethoxy)-1H-benzoimidazol-2- yl)-1H-pyrazole-4-carboxylic acid (JNJ- 42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. Mol Pharmacol 2011;79(6):910-20
90. Rosen MD, Venkatesan H, Peltier HM, et al. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase inhibitors as oral erythropoietin secretagogues. Acs Med Chem Lett 2010;1(9):526-9
91. McNeill LA, Flashman E, Buck MR, et al. Hypoxia-inducible factor prolyl hydroxylase 2 has a high affinity for ferrous iron and 2-oxoglutarate. Mol Biosyst 2005;1(4):321-4
92. Kanelakis KC, Palomino HL, Li L, et al. Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases. J Biomol Screen 2009;14(6):627-35
93. Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 2010;329(5990):407
94. Teli MK, Rajanikant GK. Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening. Mol Divers 2012;16(1):193-202
95. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
96. Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81(1):24-6
97. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575(2):266-76
98. Miyata T, Kikuchi K, Kiyomoto H, van Ypersele de Strihou C. New era for drug discovery and development in renal disease. Nat Rev Nephrol 2011;7(8):469-77
99. Warshakoon NC, Wu S, Boyer A, et al. A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 2006;16(21):5598-601
100. Takeda K, Ichiki T, Narabayashi E, et al. Inhibition of prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-alpha expression. Arterioscler Thromb Vasc Biol 2009;29(12):2132-7
101. Frohn M, Viswanadhan V, Pickrell AJ, et al. Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1alpha prolyl hydroxylase-2 inhibitors. Bioorg Med Chem Lett 2008;18(18):5023-6